Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pituitary carcinoma - case series and review of the literature.
Du Four S, Van Der Veken J, Duerinck J, Vermeulen E, Andreescu CE, Bruneau M, Neyns B, Velthoven V, Velkeniers B. Du Four S, et al. Front Endocrinol (Lausanne). 2022 Sep 8;13:968692. doi: 10.3389/fendo.2022.968692. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36157469 Free PMC article. Review.
Randomized Trial Comparing Burr Hole Craniostomy, Minicraniotomy, and Twist Drill Craniostomy for Treatment of Chronic Subdural Hematoma.
Duerinck J, Van Der Veken J, Schuind S, Van Calenbergh F, van Loon J, Du Four S, Debacker S, Costa E, Raftopoulos C, De Witte O, Cools W, Buyl R, Van Velthoven V, D'Haens J, Bruneau M. Duerinck J, et al. Among authors: du four s. Neurosurgery. 2022 Aug 1;91(2):304-311. doi: 10.1227/neu.0000000000001997. Epub 2022 May 24. Neurosurgery. 2022. PMID: 35593710 Clinical Trial.
Quality indicators in neuro-oncology: Review of the literature and development of a new quality indicator set for glioma care through a two-round Delphi survey.
Vanhauwaert D, Pinson H, Sweldens C, Du Four S, Van Eycken L; QINO consortium; De Schutter H, De Vleeschouwer S, Boterberg T. Vanhauwaert D, et al. Among authors: du four s. J Neurooncol. 2022 Apr;157(2):365-376. doi: 10.1007/s11060-022-03971-3. Epub 2022 Mar 11. J Neurooncol. 2022. PMID: 35275336
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx).
Awada G, Ben Salama L, De Cremer J, Schwarze JK, Fischbuch L, Seynaeve L, Du Four S, Vanbinst AM, Michotte A, Everaert H, Rogiers A, Theuns P, Duerinck J, Neyns B. Awada G, et al. Among authors: du four s. J Immunother Cancer. 2020 Oct;8(2):e001146. doi: 10.1136/jitc-2020-001146. J Immunother Cancer. 2020. PMID: 33067319 Free PMC article. Clinical Trial.
Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
Duerinck J, Du Four S, Bouttens F, Andre C, Verschaeve V, Van Fraeyenhove F, Chaskis C, D'Haene N, Le Mercier M, Rogiers A, Michotte A, Salmon I, Neyns B. Duerinck J, et al. Among authors: du four s. J Neurooncol. 2018 Jan;136(1):115-125. doi: 10.1007/s11060-017-2629-z. Epub 2017 Oct 7. J Neurooncol. 2018. PMID: 28988341 Clinical Trial.
26 results